Vivesto reflects the Company’s commitment to improve survival and quality of life for patients with cancer through investment in R&D and innovation
Solna, Sweden, January 19, 2022 – Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, today announces plans to change its name to Vivesto AB. The proposed name change is subject to approval at a company Extraordinary General Meeting (EGM) to be held on 21 February 2022. The new name will, after approval by the EGM, be formally registered with the Companies Registration Office following completion of the recently announced Rights Issue.
Francois Martelet, CEO, said: “Since I became CEO in March 2020, the new management team and Board has set out a focused strategy to transform the business and build an oncology-focused specialty pharmaceutical company with a diversified portfolio. We’ve strengthened our finances by reducing unnecessary operational expenditure and resolved a number of inherited legal issues, at the same time as driving the value of our existing portfolio and expanding our R&D capabilities to make us an attractive partner for promising oncology assets. As we continue to develop Cantrixil, the first in-licensed therapy in our string of pearls strategy and focus on additional in-licensing and M&A opportunities, we believe this is the right time to mark the transformed prospects of our business with a new identity. Vivesto reflects our optimism for the future and our commitment to improving survival and quality of life for patients with hard-to-treat and late-stage cancers through R&D and innovation.”
Oasmia has worked closely with the respected Brand Institute London UK to develop its new identity. Vivesto was ranked highly for brand recognition and relevance by patients, medical professionals and investors surveyed in Europe, the US and Sweden.
Online presentation today at 14:00 CET
The company will hold an online presentation today at 14:00 CET. The presentation will be given by CEO Francois Martelet and CFO Fredrik Järrsten in English. The presentation will be broadcast live via the link: https://youtu.be/SVqz40v8Wkw
Questions can be sent in advance to email@example.com or by phone to +46 72-376 90 10.
For more information:
Oasmia Pharmaceutical AB
Francois Martelet, Chief Executive Officer
Phone: +46 18-50 54 40
Consilium Strategic Communications
Jonathan Birt, Ashley Tapp
Phone: +44 (0)20 3709 5700
About Oasmia Pharmaceutical AB
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Oasmia’s shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit www.oasmia.com.